TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
<p>Abstract</p> <p>Background</p> <p>Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1)...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-04-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/10/139 |
| _version_ | 1818210585159925760 |
|---|---|
| author | Jaenicke Fritz Carney Walter Schwarz Joerg Eulenburg Christine Woelber Linn Mahner Sven Milde-Langosch Karin Mueller Volkmar |
| author_facet | Jaenicke Fritz Carney Walter Schwarz Joerg Eulenburg Christine Woelber Linn Mahner Sven Milde-Langosch Karin Mueller Volkmar |
| author_sort | Jaenicke Fritz |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.</p> <p>Methods</p> <p>Patients with epithelial ovarian cancer who presented for primary surgery were included in this study. A total of 148 serum samples from 37 patients were analyzed. Samples were prospectively collected at 4 predefined time points: 1. before radical debulking surgery, 2. after surgery and before platinum/taxane based chemotherapy, 3. during chemotherapy, 4. after chemotherapy. Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.</p> <p>Results</p> <p>Serum levels of all markers changed substantially during first-line therapy. High CA-125 (p = 0.002), TIMP-1 (p = 0.007) and VEGF-165 (p = 0.02) after chemotherapy were associated with reduced overall survival. In addition, elevated CA-125 (p < 0.001) and VEGF-165 (p = 0.006) at this time point predicted poor progression-free survival. TIMP-1 and VEGF-165 were closely correlated at all time-points during therapy.</p> <p>Conclusions</p> <p>TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients and predicted prognosis. These findings support the role of angiogenesis in ovarian cancer progression and the use of antiangiogenic therapy.</p> |
| first_indexed | 2024-12-12T05:18:56Z |
| format | Article |
| id | doaj.art-19e9be76147d49b0ac97269c8f3b898a |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-12T05:18:56Z |
| publishDate | 2010-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-19e9be76147d49b0ac97269c8f3b898a2022-12-22T00:36:39ZengBMCBMC Cancer1471-24072010-04-0110113910.1186/1471-2407-10-139TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patientsJaenicke FritzCarney WalterSchwarz JoergEulenburg ChristineWoelber LinnMahner SvenMilde-Langosch KarinMueller Volkmar<p>Abstract</p> <p>Background</p> <p>Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.</p> <p>Methods</p> <p>Patients with epithelial ovarian cancer who presented for primary surgery were included in this study. A total of 148 serum samples from 37 patients were analyzed. Samples were prospectively collected at 4 predefined time points: 1. before radical debulking surgery, 2. after surgery and before platinum/taxane based chemotherapy, 3. during chemotherapy, 4. after chemotherapy. Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.</p> <p>Results</p> <p>Serum levels of all markers changed substantially during first-line therapy. High CA-125 (p = 0.002), TIMP-1 (p = 0.007) and VEGF-165 (p = 0.02) after chemotherapy were associated with reduced overall survival. In addition, elevated CA-125 (p < 0.001) and VEGF-165 (p = 0.006) at this time point predicted poor progression-free survival. TIMP-1 and VEGF-165 were closely correlated at all time-points during therapy.</p> <p>Conclusions</p> <p>TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients and predicted prognosis. These findings support the role of angiogenesis in ovarian cancer progression and the use of antiangiogenic therapy.</p>http://www.biomedcentral.com/1471-2407/10/139 |
| spellingShingle | Jaenicke Fritz Carney Walter Schwarz Joerg Eulenburg Christine Woelber Linn Mahner Sven Milde-Langosch Karin Mueller Volkmar TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients BMC Cancer |
| title | TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients |
| title_full | TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients |
| title_fullStr | TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients |
| title_full_unstemmed | TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients |
| title_short | TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients |
| title_sort | timp 1 and vegf 165 serum concentration during first line therapy of ovarian cancer patients |
| url | http://www.biomedcentral.com/1471-2407/10/139 |
| work_keys_str_mv | AT jaenickefritz timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT carneywalter timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT schwarzjoerg timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT eulenburgchristine timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT woelberlinn timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT mahnersven timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT mildelangoschkarin timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients AT muellervolkmar timp1andvegf165serumconcentrationduringfirstlinetherapyofovariancancerpatients |